Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vera Golder

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Australian Family Physician|November 13, 2013
Ankylosing spondylitis: an updateVera Golder, Lionel Schachna
The Medical Journal of Australia|March 17, 2017
Systemic lupus erythematosus: an updateVera Golder, Alberta Hoi
The Journal of Rheumatology|January 17, 2017
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge GapVera Golder, Eric F Morand, Alberta Y Hoi
Rheumatology (Oxford, England)|December 6, 2020
Treatment targets in SLE: remission and low disease activity stateVera Golder, Michel W P Tsang-A-Sjoe
The Lancet. Rheumatology|January 30, 2024
Clinician-reported outcome measures in lupus trials: a problem worth solvingKathryn Connelly, Vera Golder, Rangi Kandane-Rathnayake, et al.
Annals of the Rheumatic Diseases|January 23, 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, et al.
Rheumatology (Oxford, England)|October 19, 2021
Measurement of specific organ domains in lupus randomized controlled trials: a scoping reviewKathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Emerging Infectious Diseases|August 21, 2015
Disseminated Enteroviral Infection Associated with ObinutuzumabClaire Dendle, Michael Gilbertson, Tony M Korman, et al.
Early Human Development|January 15, 2013
Autonomic cardiovascular control in hypotensive critically ill preterm infants is impaired during the first days of lifeVera Golder, Michele Hepponstall, Stephanie R Yiallourou, et al.
Annals of the Rheumatic Diseases|January 26, 2019
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosusShereen Oon, Molla Huq, Vera Golder, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Australian Family Physician|November 13, 2013
Ankylosing spondylitis: an updateVera Golder, Lionel Schachna
The Medical Journal of Australia|March 17, 2017
Systemic lupus erythematosus: an updateVera Golder, Alberta Hoi
The Journal of Rheumatology|January 17, 2017
Quality of Care for Systemic Lupus Erythematosus: Mind the Knowledge GapVera Golder, Eric F Morand, Alberta Y Hoi
Rheumatology (Oxford, England)|December 6, 2020
Treatment targets in SLE: remission and low disease activity stateVera Golder, Michel W P Tsang-A-Sjoe
The Lancet. Rheumatology|January 30, 2024
Clinician-reported outcome measures in lupus trials: a problem worth solvingKathryn Connelly, Vera Golder, Rangi Kandane-Rathnayake, et al.
Annals of the Rheumatic Diseases|January 23, 2023
Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosusEric F Morand, Gabriel Abreu, Richard A Furie, et al.
Rheumatology (Oxford, England)|October 19, 2021
Measurement of specific organ domains in lupus randomized controlled trials: a scoping reviewKathryn Connelly, Jeevan Vettivel, Vera Golder, et al.
Emerging Infectious Diseases|August 21, 2015
Disseminated Enteroviral Infection Associated with ObinutuzumabClaire Dendle, Michael Gilbertson, Tony M Korman, et al.
Early Human Development|January 15, 2013
Autonomic cardiovascular control in hypotensive critically ill preterm infants is impaired during the first days of lifeVera Golder, Michele Hepponstall, Stephanie R Yiallourou, et al.
Annals of the Rheumatic Diseases|January 26, 2019
Lupus Low Disease Activity State (LLDAS) discriminates responders in the BLISS-52 and BLISS-76 phase III trials of belimumab in systemic lupus erythematosusShereen Oon, Molla Huq, Vera Golder, et al.
Pageof 5